Title of Invention

AN ANTIOXIDANT SYNERGISTIC COMPOSITION FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION

Abstract The present invention relates to a novel antioxident formulation for treatment of acute myocardial infarction for prevention of remodeling and heart failure comprising mixing the following anti-oxident in the proportion indecated there against: Coenzyme Q10(Ubiquinone)- 45%-57.5% by wt. Trimetazidine - 30%-40.0% by wt. Lovastatin - 1.5%-15% by wt. and the balance if any a conventional filler for preparing the tablet or capsule.
Full Text Form 2
THE PATENTS ACT, 1970
COMPLETE SPECIFICATION
Section 10
"AN ANTIOXIDANT SYNERGISTIC COMPOSITION FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION"
Prof. Ram Bahadur Singh, Prof. Adarsh Kumar, Dr Mohammad Arif Niaz of Shiv Niketan, 1st Floor, Flat No. 7, 18th Road, Khar West, Mumbai-400050, Maharashtra, India.
2 7 JUL 2007
The following specification particularly describes and ascertains the nature of this invention and the manner in which it is performed.


This invention relates to a novel antioxidant formulation for treatment of acute myocardial infarction for prevention of remodeling and heart failure.
Background:
Oxidative damage in association with antioxidant deficiency have been observed in patients with AMI. Superoxide and hydroxyl radicals and hydrogen peroxides are important reactive oxygen species in the pathogenesis of cardiac damage resulting remodeling and heart failure among these patients (l-4).Case control studies indicate that there is a deficiency of antioxidant vitamins A,E,C and betacarotene, CoQ10,lycopene and increased free radical damage in the form of higher thiobarbituric acid reactive substances, MDA and diene conjugates in patients with AMI and heart feilure(l-5).CoQ10 and trimetazidine are potent antioxidant agents which are known to increase the production of ATP and energy in the myocardial cell(3-6). It is possible that antioxidant and bioenergetic activity of these agents may have synergistic effects in patients with AMI because these patients are known to have enormous amount of free radical stress and low level of ATP due to myocardial ischaemia. Addition of statins to this combination may further enhance mis activity and improve endothelial function which is beneficial in these patients- No other study has examined the role of antioxidants, bioenergetics and statins in combination in patients with AMI and heart failure. The role of CoQIO in heart failure and the effect of trimetazidine in coronary artery disease(CAD) are known however the dosages and efficacy are controversiaL
The object of this invention is to examine the role of this combination of antioxidants in patients with AMI for prevention of remodeling in AMI and in a sub-study to find out whether it is also beneficial and safe in conjunction with statin and thereafter develop a composition for the treatment of AMI and prevention of remodeling and heart failure.
SUMMARY OF THE INVENTION:
The present invention provides a novel antioxidant composition for treatment of acute myocardial infarction for prevention of remodeling and heart failure comprising the following anti-oxidants in the proportion indicated there against:
Coenzyme Q10 (Ubiquinone) - 45% - 57.5% by wt.
Trimetazidine - 30% - 40.0% by wt.
Lovastatin 1.5%- 15% by wt.

and the balance if any a conventional filler for preparing the tablet or capsule.
Said filler is cellulose.
The ingredients are in the following proportions:
Coenzyme Q10 (Ubiquinone) - 57.14 % by wt.
Trimetazidine - 38.1% by wt.
Lovastatin - 4.76% by wt.
The ingredients are in the following proportions:
Coenzyme Q10 (Ubiquinone) - 45.28% by wt.
Trimetazidine - 30.18% by wt.
Lovastatin - 1.9 % by wt.
Filter - 22.64 % by wt
The ingredients are in the following proportions:
Coenzyme Q10 (Ubiquinone) - 5625 % by wt.
Trimetazidine - 37.5 % by wt.
Lovastatin - 6.25 % by wt.
The ingredients are in the following proportions:
Coenzyme Q10 (Ubiquinone) - 50 % by wt.
Trimetazidine - 33.3% by wt.
Lovastatin - 4.2 % by wt.
Filler - 12.5% by wt.
The invention now will be described with reference to the following examples: Example 1:
The test agent ingredients, coenzymeQlO, trimetazidine and lovastatin were were mixed in the following proportions and capsules prepared were of 52.5mg.


Example 2:
The test agent ingredients, coenzyme Q10, trimetazidine and lovastatin were purchased were mixed in the following proportions and thereafter they were filled in capsules with cellulose. The capsules prepared were of 132.5mg.
Coenzyme Q10 - 60mg
Trimetazidine - 40mg
Lovastatin - 2.5mg
Cellulose - 30mg
Example 3:
The test agent ingredients, coenzyme Q10,trimetazidine and lovastatin were were mixed in the following proportions and thereafter they were filled in capsules. The capsules prepared were of 160.0mg.
Coenzyme Q10 - 90mg
Trimetazidine - 60mg
Lovastatin - lOmg
Example 4:
The test agent ingredients, coenzyme Q10, trimetazidine and lovastatin were mixed in the following proportions and thereafter they were filled in capsules with cellulose. The capsules prepared were of 240.0mg.
Coenzyme Q10 - 120mg
Trimetazidine - 80mg
Lovastatin - 10 mg
Cellulose - 30mg
CLINICAL TRIALS FOR DEVELOPMENT OF PROCESS:
The effects of individual ingredients in moderate, higher and in combination were studied by administering coenzyme QlO+trimetazidine in single and double blind trials with and without control groups for a period of 4 weeks to study their synergistic effects (Tables 1-5). A randomized, double blind trial was conducted in 73 intervention and 71 control group patients of AMI for treatment and prevention of remodeling and heart failure during a follow up of 24 weeks. Results were also calculated after 4 weeks.

1. Effects of individual antioxidants in moderate doses:
We administered coenzyme Q10 (60 mg/day), trimetazidine (40mg/Day) and lovastatin. (10 mg/day) after randomizing the subjects into three groups (Table 1). There was a modest reduction in TBARS, MDA and diene conjugates in the coenzyme Q10 group, doubtful beneficial effect in the trimetazidine group and no effect in lovastatin group. The changes were nonsignificant.
2. Effects of individual antioxidants in higher doses:
Subjects were randomized in to three groups in a double blind fashion. They were administered, coenzyme QtO (120 mg/day) or trimetazidine(80 mg/day) or lovastatin (10 mg/day) in the concerned group for a period of 4 weeks. Treatment with coenzyme Q10 was associated with substantial reduction in TBARS, MDA and diene conjugates and an increase in vitamin. E,C and betacarotene (Table 2). Treatment with trimetazidine also caused substantial changes but slightly lower than coenzyme Q10. Lovastatin had neutral effect.
3. Effects of two combined antioxidant formulation in higher doses:
Subjects were randomized into three groups (after a wash out period of 4 weeks) in a double blind fashion. They were administered coenzyme Q10 + trimetazidine, Coenzyme QlO+lovastatin and trimetazidine + lovastatin. There was a substantial reduction in TBARS, MDA and diene conjugates and increase in Vitamin E,C and beta carotene indicating that some synergistic effect is possible.
4. Effect of three combined antioxidant formulations in various doses:
Subjects were randomized into three groups as given table 4 and were administered various combinations of formulations in a double blind fashion for 4 weeks. High dose combination of coenzyme Q10 (200 mg) +trimetazidine (80 mg) +lovastatin (10 mg) per day showed a marked reduction in TBARS, MDA and diene conjugates and increase in vitamins E,C and beta carotene but lower compared to high dose combination.
Study Methods:
Patients of CAD were recruited by giving advertisements in the newspapers that heart disease may be slowed by treatment with antioxidants and antianginal drugs may be stopped in some patients. The diagnosis of CAD was based on available record indicating CAD. The main criteria for inclusion in the study was a serum creatinine level of Subjects and Methods for Final Trial:


Clinical trial in patients with AMI were conducted to determine the effective dosage and combinations. Finally, subjects (n=144) with proven AMI were stratified into anterior or inferior AMI of at the most 72 hours duration and were randomly divided into antioxidant (n=73) and control (n=71) groups by blindly selecting a card. Treatment:
The test agent antioxidant coenzyme Q10, trimetazidine and lovastatin are marketed as health products in most industrialized countries and are used for the treatment of heart attack and heart failure and other illnesses indicating that they are safe for human trial. The placebo capsules containing inert fibre were supplied from our laboratory. All patients in the treatment group (group A) were given two capsules twice daily. The placebo capsules (two, twice daily) containing inert fibre were administered to all patients in the placebo group B. The test capsules were identical in shape, size and colour for both groups and were provided to patients in containers marked group A or B that were identical in all other respects. Compliance was monitored by counting the number of capsules returned by the patients from either container, A or B on follow-up visits or on each day during hospitalization. All other advises on treatments were similar in both groups who met for checkup to physician blind to groups.
Study Design for Trial in AML
All the patients with the diagnosis of AMI or unstable angina were randomized to two groups. The study was approved by the ethics committee of human studies in our center. After written informed consent, all patients with the above diagnosis were randomized by the pharmacist to receive either antioxidant capsules or placebo capsules. The physician examining the patients and technicians analyzing the blood were blinded to treatment groups. All patients were asked to select blindly one of the cards, each enclosed in a sealed envelope and marked either group A or B. The intervention group A (n=73) received antioxidant formulation (2 cap twice daily) and the placebo group B (n=71) received inert fibre cellulose (2 cap twice daily, 52.5 mg each) for a period of 4 and 24 weeks. Ail other treatments such as trinitrates, aspirin, streptokinase, beta blockers, A,C, E inhibitors were administered to both the groups. All patients were followed weekly for 4 weeks and then every 4 weekly for 12 weeks.
Clinical, echocardiographic radiologic and laboratory data were recorded at admission before entry to the study. Hypertension was defined as blood pressure > 140/90 mm/Hg and hypotension as systolic blood pressure
pressure was >140 mm/Hg systolic and or >90 mm/Hg diastolic with an attempt to maintain blood pressure A blood sample after at least 10 hours of fasting was drawn at entry and then 4, 8 and 12 week of follow up in the morning and was analyzed for blood count, cardiac enzymes, T vitamin, E and C and beta-carotene and thiobarbituric acid reactive substance (TBARS), diene conjugates and malondialdehyde (MDA) (16-20). Laboratory personnel analyzing the blood were blind to groups. Statistical analysis:
The two-sample t-test using one-way analysis of variance and the Z score for proportions were used to measure the statistical significance between the two groups. Turnkeys post-hoc test was also conducted for multiple comparisons. Only a P. Value RESULTS:
The new process revealed that a combination of coenzyme Q10 (120mg/day)+ trimetazidine (80mg/day) in the given doses due to their synergistic effect was most effective combination. Data were analyzed after dividing the subjects into 2 groups; antioxidant group (n=73)and placebo group(n=71).Antioxidant group showed a significant decline in TBARS,MDA and diene conjugates and a significant increase in antioxidant vitamins E,C and beta-carotene. Effect on Cardiac Events: After 4 weeks of follow-up on treatment with this new formulation, there was a significant decrease in the total cardiac events including nonfatal myocardial infarction and deaths in the antioxidant group compared to control group (15% vs 30.9%,PO.02Xtables 6-9). The frequency of angina, arrhythmias and left ventricular dysfunction were not significantly different at entry to the study. However after 4 weeks, CoQ + trimetazidine group showed significant benefit in cardiac events and all other parameters including left ventricular dysftmction (table 7-9 ).The subgroup within group A taking lovastatin showed greater benefit in all these parameters compared to the group not taking lovastatin. Effects on Remodeling:
Subgroup having poor ejection fraction showed significant decrease in all the echocardiographic parameters indicating reduction in remodelling compared to the control group. However, antioxidant group as a whole and subjects with low

ejection fraction( Effective Range of Dosages of Various Agents:
Table 5 shows that optimal dosages for reversing oxidative damage in patients with CAD were: coenzyme Q10, 120 mg/day, trimetazidine (80 mg/day) and lovastatin (10 mg/day). It is clear that the effective ranges of doses of these agents in a combination should be; coenzyme Q10,60-120mg/day, trimetazidine, 40-80 mg/day, lovastatin 10-12 mg/day. In mg/kg body weight the dosages could be coenzyme Q10, 2mg, trimetazidine, 1.34 mg and lovastatin, 0.17 mg/day. DISCUSSION:
This study shows that the proposed newly processed antioxidant formulation with new dosages was effective and the content have synergistic effects. Treatment with this combined antioxidant formulation containing coenzyme Q10, trimetazidine and in a subgroup in patients with AMI was associated with a significant decline in oxidative damage leading to beneficial effect on angina, arrhythmia's, heart failure and remodeling after 4 and 24 weeks of follow-up in the antioxidant groups compared to control groups (Table 7-10). No published evidence is available to demonstrate the role of antioxidants and statins in-patients with AMI. It is therefore possible that in patients with AMI, with or without low ejection fraction treatment with antioxidants and statins may have reverse oxidative damage due to its potent antioxidant and ATP sparing (bioenergetic) effects and their synergistic activity in our patients. The protective effects were apparent within 4 weeks of therapy with antioxidants indicating that the effect may be on myocardial and coronary artery endothelial function, thrombosis and left ventricular function. The benefit may also be due to anti-inflammatory and membrane stabilizing activity of antioxidants. In case control studies, plasma levels of coenzyme Q10 and vitamin A,E and C, selenium, lycopene, and antioxidant enzymes such as superoxide dismutase, catalase etc. were inversely associated with AMI and heart failure. Deficiency of vitamin E and C and beta-carotene and oxidative damage in the form of high TBARS, malondialdehyde and diene conjugates were also observed in our study in both the groups indicating that oxidative stress may be an important mechanism of myocardial injury and oxidative damage(21-26).
Experimental studies have incriminated reactive oxygen species as primary mediators in the pathogenesis of ischemic, toxic and immunologically mediated in reperfusion myocardial cell injury.(1-4) Overproduction of free radicals by blood borne cells or myocardial cells in presence of poor expression of antioxidant enzymes(5-7) can promote both direct oxidant injury and indirect

effects including activation and potentiation of inflammatory mediators. Among characteristics are more leads to chronic inflammation. Cell injury is characterized with first by efflux of adenine metabolites, CPK enzymes and decline in ATP levels and then by cell detachment and cell lysis. The ability of antioxidants to decrease the loss of myocardial function as a result of oxidative injury appears to be due to its antioxidant and anti-inflammatory properties and ATP generation by CoQ10.
There is evidence of a synergistic action of coenzyme Q10+ trimetazidine as well as of lovastatin in experimental studies and coenzyme Q10 can spare vitamin E in the tissues on treatment. Antioxidant bioenergetic supplementation in patients with AMI and heart failure might prevent ultimate heart failure. It may interfere with disease progression or it may reverse partial cardiac damage by cell growth and at least it may slow down the deteriorating cardiac function to a more acceptable rate. Antioxidant bioenergetic statin combination may have no effect on scarred myocardium but can prevent cell dysfunction.
In brie£ the findings of our trial indicate that the newly processed antioxidant bioenergetic formulation in a new dosage form can reverse oxidative damage, decrease cardiac events, heart failure, angina pectoris, arrhythmia's as well as remodeling and heart failure in patients with failure in patients with AMI.
Conclusions: Treatment with newly processed antioxidant and bioenergetic formulation in given dosages due to a synergistic effect reduces oxidative damage and cardiac events, remodeling and heart fiulure in the treatment group than control group.

REFERENCES:
1. Grech ED, Jackson M, Ramsdale DR. Reperfiision injury after acute myocardial infarction. Br Med J 1995;310:477-478.
2. Ceremuzynski L. Hormonal and metabolic reactions evoked by acute myocardial infarction. Circ Res 1981 ;48:765-776.
3. Singh RB, Niaz MA, Rastogi S, Sharma JP, Kumar R, Bishnoi I, Beegom R. Plasma levels of antioxidant vitamins and oxidative stress in patients with suspected acute myocardial inferction. Acta Cardiol 1994;49:441-452.
4. Zalewski A, Savage M, Goldberg S. Protection of the ischemic myocardium during percutaneous transluminal coronary angioplasty Am J Cardiol 1988;61:54G-60G.
5. Maridonneau-Parini I, Harppey C. Effects of trimctazidine on membrane damage induced by oxygen free radicals in human cells. Br J Clin Pharmacol 1985,20: 148-51.
6. Atar D, Mortensen SA, Flachs H, Herzog WR. Coenzyme QIO protects ischemic myocardium in an open-chest swine model. Clin Investig 1993;71:S 103-111.
7. Herzog WR, Schlossberg ML, Mortensen SA, Serebruany VL. Dietary supplementation with coenzyme Q10 reduces platelet aggregability in swine Coenzyme Q. Res Biol Med 1995;3:5-8.
8. Serebruany VL, Ordonez JV, Herzog WR, Morten R, Mortensen SA, Folkers K, Gurbel PA. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human Vitronectin (CDSI/CD61) receptor expression. J Cardiocase Pharmacol 1997;29:16-22.
9. Singh RB, Niaz MA, Rastogi V, Rastogi SS. Coenzyme Q in cardiovascular disease. J Assoc Physiol India 1998;48:299-306.
10.Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamasaki N. Effects
of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris.
Am J Cardiol 1985;56:247-257. 11 .Hofman-Bang C, Rehnqvist N, Swedberg K, Astrom H. Coenzyme Q10 as
an adjunctive in treatment of congestive heart failure. J Am Coll Cardiol
1992;19(Suppl.)774~776. 12.Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and
antioxidants in acute myocardial infarction. Mol Aspect Med
1994:15(Suppl.)143447. 13.Kontush A, Reich A, Baum K, Spranger T, Finckh B, Kohlschutter A,
Beisiegel U. Plasma ubiquinol is decreased in patients with hyperlipidemia.
Atherosclerosis 1997:129:119-126. 14.Yokoyama H, Lingle DM, Crestanello JA, et al. Coenzyme Q10 protects
coronary endothelial function from ischaemia reperfiision injury via an
antioxidant effect. Surgery 1996;120:189-196.

+
15.Baggio G, Gatidini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme QIO as adjunctive therapy in heart failure. Mol Aspects Med 1994; 15(Suppl. )287-294.
16.Soja AM, Mortenscn SA Treatment of congestive heart failure with coenzvme QIO illuminated by meta-analysis of clinical trials. Mol Aspects Med 1997:18(SuppL):l 59-169.
l7.Waters D,Higginson L,Gladstone P et al.Eftects of cholesterol lowering on
progression of coronary atherosclerosis in women.Circulation. 1995,92:2404-10.
Table 1: Effects of individual antioxidants in moderate doses in patients with
coronary artery disease. ■
Datum (Normal range) Coenzyme QIO (60 mg/day)
Trimetazidine(40 mg/day) Lovastatin (10 mg/day)
Baseline(n=6) After 4 week
Baseline(n=6) After 4 week Baseline(n=6) After 4 week
0.42 0.68 0.64
0.13 0.28 0.16 0.28
10.5 19.6 11.6 18.0
1.63 1.20 1.54 1.24
2.85 2.02 2.78 2.05
27.8 25.0 28.6 24.8
Vitamin E (0.6-0.95 mg/dl) Vitamin C (0.28-0.53 mg/dl) Beta-carotene (18.8-29.5mg/dl) TBARS (0.1-0.6 muol/ml) MDA (1.2-3.5 nmol/ml) Diene conjugates (20-25,OD)
Benefit +
Values are means TBARS = thiobarbituric acid reactive substances.MDA = Malondialdehyde
Table 2: Effects of individual antioxidants in higher doses in patients with coronary artery disease.
Coenzyme Q10 (120 mg/day)
1 nmetazidme(80mg/day) Lovastatin(10 mg/day)
Baseline After 4 week Baseline
After 4 week Baseline After 4 week
Vitamin E (mg/dl) 0.43 0.76 0.44 0 70 0 45 0 55
VitaminC(mg/dl) 0.06 0.19 0.07 0 18 007 0 11
Beta-carotene (mg/dl) 10.60 22.70 10.6 20 8 102 15 3
TBARS (nmol/ml) 1.32 1.02 1.34 105 132 I 16
MDA(nmoI/ml) 2.44 2.01 2.44 2 12 238 221
Diene conjugates (OD) 26.6 24.0 26.4 25 1 266 25 3

Benefit
Values are means

+-+ +

Table 3: Effects of two combined antioxidant formulation in higher doses in patients with coronary artery disease

Coenzyme Q10 (120mg/day)
Trimetazidme (80 mg/day) Coenzyme Q10 (120 mg/day)
+Lovastatinq(10 mg/day) +Trimetazidine (80 mg/day)
After 4 week
Baseline After 4 week Baseline
Baseline After 4 week


Vitamin E Vitamin C Beta-carotene 0.46 0.18 10.0 0.73 0.36 23.2 0.65 0.19 11.1 0.74 0.35 22.5
TBARS 1.6 1.4 1.4 1.0

2.0 25.6
2.9 28.9
2.4 25.0
MDA
Diene conjugates
2.5 29.0
-*-+
Benefit
Values are means Dosages: Coenzyme Q10, l-2mg/kg body weight, trimetazidine = .67-1.3 mg/kg body weight, lovastatin = .6-1.2 mg/kg body weight.
Table 4: Effect of three combined antioxidant formulations in various doses in
patients of coronary artery disease.
Coenzyme Q10 (120mg/day) Coenzyme
Q10(90 mg/day) ■ Coenzyme Q10 (60mg/day)
+Trimetazidine (80 mg/day)
+Trimetazidine (60 mg/day) +Trimetazidine (40 mg/day)
+Lovastatin( 10 mg/day) +Lovastatin
(10 mg/day) +Lovastatin (10 mg/day)^
Baseline After 4 week Baseline
After 4 week Baseline After 4 week
Vitamin E 0.42 0.78 0.41 0.63
Vitamin C 0.10 0.38 0.10 0.31
Beta-carotene 11.5 25.6 10.8 21.7
TBARS 1.54 1.0 1.55. 1.32
MDA 2.88 1.5 2.92 2.31
Diene conjugates 29.6 24.0 29.6 26.0
Benefit +++ TT
Values are means.









We claim:
1. An antioxidant synergistic composition for treatment of acute myocardial infraction
comprising the following anti-oxidants in the proportions indicated there against:
Coenzyme Q10 (Ubiquinone) - 45%-57.5% by wt.
Trimetazidine - 30%-40.0% by wt.
Lovastatin - 1.5%-15% by wt.
And the balance a conventional filler.
2. A composition as claimed in claim 1 wherein said filler is cellulose.
3. A composition as claimed in claim 1 wherein the ingredients are in the following proportions.
Coenzyme Q10 (Ubiquinone) - 57.14% by wt.
Trimetazidine - 38.1% by wt.
Lovastatin - 14.76% by wt.
4. A composition as claimed in claim 1 or 2 wherein the ingredients are in the following
proportions:
Coenzyme Q10 (Ubiquinone) - 45.28% by wt.
Trimetazidine - 30.18% by wt.
Lovastatin - 1.9% by wt.
Filler - 22.64% by wt
5. A composition as claimed in claim 1 wherein the ingredients are in the following
proportions:
Coenzyme Q10 (Ubiquinone) - 56.25% by wt.
Trimetazidine - 37.5% by wt.
Lovastatin - 6.25% by wt.
6. A composition as claimed in claim 1 and 2 wherein the ingredients are in the following
proportions:
Coenzyme Q10 (Ubiquinone) - 50% by wt.
Trimetazidine - 33.3% by wt.
Lovastatin - 4.2% by wt.
Filler - 12.5% by wt
7. A new antioxidant composition for treatment of acute myocardial infarction substantially
as herein described with reference to the foregoing examples.
Dated this 1st day of March, 2001
Of Anand and Anand, Advocates Agents for the Applicant

Documents:

361-mum-2001-abstract(23-4-2001).pdf

361-mum-2001-abstract(granted)-(29-1-2011).pdf

361-mum-2001-cancelled pages(23-04-2001).pdf

361-mum-2001-cancelled pages(27-7-2007).pdf

361-mum-2001-claims(23-4-2001).pdf

361-mum-2001-claims(27-07-2007).doc

361-mum-2001-claims(27-07-2007).pdf

361-mum-2001-claims(granted)-(29-1-2011).pdf

361-MUM-2001-CORRESPONDENCE(21-8-2008).pdf

361-mum-2001-correspondence(27-07-2007).pdf

361-mum-2001-correspondence(8-10-2007).pdf

361-mum-2001-correspondence(ipo)-(30-06-2008).pdf

361-mum-2001-correspondence(ipo)-(31-1-20111).pdf

361-mum-2001-description(complete)-(23-4-2001).pdf

361-mum-2001-description(granted)-(29-1-2011).pdf

361-mum-2001-form 1(23-04-2001).pdf

361-mum-2001-form 1(27-07-2007).pdf

361-mum-2001-form 18(02-01-2005).pdf

361-mum-2001-form 18(30-12-2005).pdf

361-mum-2001-form 2(23-4-2001).pdf

361-mum-2001-form 2(complete)-(27-07-2007).doc

361-mum-2001-form 2(complete)-(27-07-2007).pdf

361-mum-2001-form 2(granted)-(29-1-2011).pdf

361-mum-2001-form 2(title page)-(23-4-2001).pdf

361-mum-2001-form 2(title page)-(granted)-(29-1-2011).pdf

361-mum-2001-form 3(23-04-2001).pdf

361-mum-2001-form 3(27-07-2007).pdf

361-mum-2001-petition under rule 137(27-07-2007).pdf

361-mum-2001-petition under rule 138(27-7-2007).pdf

361-mum-2001-power of attorney(27-07-2007).pdf

361-mum-2001-power of authority(27-7-2007).pdf

361-mum-2001-specification(amanded)-(27-7-2007).pdf

361-mum-2001-specification(amended)-(27-7-2007).pdf


Patent Number 245689
Indian Patent Application Number 361/MUM/2001
PG Journal Number 05/2011
Publication Date 04-Feb-2011
Grant Date 29-Jan-2011
Date of Filing 23-Apr-2001
Name of Patentee PROF RAM BAHADUR SINGH,PROF ADARSH KUMAR AND DR MOHAMMAD ARIF NIAZ.
Applicant Address Shiv Niketan, 1st Floor, Flat No.7, 18th Road, Khar West, Mumbai-400 050
Inventors:
# Inventor's Name Inventor's Address
1 RAM BAHADUR SINGH, ADARSH KUMAR AND MOHAMMAD ARIF NIAZ Shiv Niketan,1st Floor, Flat No.7,18th Road, Khar West,Mumbai-400 050
PCT International Classification Number A61P39/00
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 NA